Feed/Investors/Intermediate Capital Group (ICG)

Intermediate Capital Group (ICG)

The rounds this investor is named on, who it invests beside, and where it shows up.

Named on one round in the feed.

Since 2021-07-15

ROUNDS

joined, none as lead

ROUNDS JOINED · USD

$172M

across 1 round

LATEST ROUND

Series B · $172M · 2021-07-15

CO-INVESTORS

named beside it

Rounds

[ 1 ]

The rounds this investor is named on, who it invests beside, and where it shows up.

Company	Round	Amount	Announced	Role
Allotera Therapeutics Allotera Therapeutics develops allogeneic T-cell therapies targeted at treating various types of blood cancers like leukemia and lymphoma.	Series B Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$172M	2021-07-15	[ PART ]